

1 **Multisystemic inflammatory syndrome following COVID-19 mRNA vaccine in children: a**
2 **national post-authorization pharmacovigilance study**

3
4 Naïm Ouldali, M.D., Ph.D.,^{1,2,3,4}, Haleh Bagheri, Pharm.D., Ph.D.,⁵, Francesco Salvo, M.D.,
5 Ph.D.,^{6,7}, Denise Antona, M.D.,⁸, Antoine Pariente, M.D., Ph.D.,⁹, Claire Leblanc, M.D.,¹
6 Martine Tebacher, M.D., Ph.D.,¹⁰, Joëlle Micallef, M.D., Ph.D.,^{11,12}, Corinne Levy, M.D.,^{3,13}
7 Robert Cohen, M.D.,^{3,13}, Etienne Javouhey, M.D., Ph.D.,^{14,15}, Brigitte Bader-Meunier,
8 M.D.,^{16,17}, Caroline Ovaert, M.D., Ph.D.,^{18,19}, Sylvain Renolleau, M.D., Ph.D.,^{20,21}, Veronique
9 Hentgen, M.D., Ph.D.,^{22,23}, Isabelle Kone-Paut, M.D.,^{23,24}, Nina Deschamps, M.D.,²⁵, Loïc De
10 Pontual, M.D., Ph.D.,²⁶, Xavier Iriart, M.D.,^{27,28,29}, Christelle Gras-Le Guen, M.D.,
11 Ph.D.,^{30,31,32}, François Angoulvant, M.D., Ph.D.,^{1,33}, Alexandre Belot, M.D., Ph.D.,^{34,35,36}, and
12 the “French Covid-19 Paediatric Inflammation Consortium”[£] and the “French
13 Pharmacovigilance network”^{*}
14
15

16 **Authors affiliations:**

17 ¹ Assistance Publique-Hôpitaux de Paris, Department of general paediatrics, paediatric infectious disease and
18 internal medicine, Robert Debré university hospital, Université de Paris, Paris, France.
19 ² Infectious Diseases Division, CHU Sainte Justine - Montreal University, Montreal, Quebec, Canada.
20 ³ ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France.
21 ⁴ Université de Paris, INSERM UMR 1123, ECEVE, Paris, France
22 ⁵ Department of Medical and Clinical Pharmacology, Regional Pharmacovigilance Center, CIC 1436,
23 Toulouse University Hospital, France
24 ⁶ INSERM, BPH, U1219, Team Pharmacoepidemiology, Université de Bordeaux, 33000 Bordeaux, France
25 ⁷ Pole de Santé Publique, Service de Pharmacologie Médicale, Regional pharmacovigilance center of
26 Bordeaux, CHU de Bordeaux, 33000 Bordeaux, France.
27 ⁸ Santé Publique France, Agence nationale de Santé publique, Saint-Maurice, France
28 ⁹ Team Pharmacoepidemiology, Bordeaux University, INSERM, U1219 BPH Research Center, Bordeaux,
29 France
30 ¹⁰ Regional pharmacovigilance center of Strasbourg, HUS, Strasbourg, France
31 ¹¹ Marseille University hospital, Clinical pharmacology department Regional Pharmacovigilance Center of
32 Marseille, France
33 ¹² Aix-Marseille University, INSERM UMR 1106, Marseille, France.
34 ¹³ Centre Hospitalier Intercommunal, Research Center, Université Paris Est, IMRB-GRC GEMINI, Créteil,
35 France.
36 ¹⁴ Hospices Civils de Lyon, Paediatric Intensive Care Unit, Hopital Femme, Mère Enfant, University of Lyon,
37 Bron, France
38 ¹⁵ EA 7426 "Pathophysiology of Injury-Induced Immunosuppression", University Claude Bernard Lyon 1,
39 Hospices Civils of Lyon, Lyon, France.
40 ¹⁶ Department of Paediatric Hematology-Immunology and Rheumatology, Necker-Enfants Malades Hospital,
41 AP-HP, Paris, France, Reference center for Rheumatic, AutoImmune and Systemic diseases in children
42 (RAISE), Paris, France.
43 ¹⁷ Laboratory of Immunogenetics of Paediatric Autoimmunity, Imagine Institute, Inserm U 1163, Paris
44 University, Paris, France
45 ¹⁸ Department of Pediatric Cardiology, Hôpital Timone Enfant, AP-HM, Marseille, France.
46 ¹⁹ Aix-Marseille University, MMG, INSERM, Marseille, France.
47 ²⁰ Pediatric Intensive Care Unit, Necker Hospital, AP-HP, Paris University, Paris, France
48 ²¹ Paris University, EA7323, Paris, France.
49 ²² General Pediatrics department, Versailles Hospital, Paris, France.
50 ²³ CEREMAIA (French reference center for auto-inflammatory diseases and inflammatory amyloidosis), Paris,
51 France.
52 ²⁴ Pediatric Rheumatology Department, Bicêtre Hospital, APHP, University of Paris Saclay, Kremlin Bicêtre,
53 France.
54 ²⁵ General Pediatrics department, Saint-Malo Hospital, Saint-Malo, France.
55 ²⁶ General Pediatrics and Pediatric emergency department, Jean Verdier Hospital, Bondy, France.
56 ²⁷ Department of Pediatric and Adult Congenital Cardiology, Bordeaux University Hospital, Pessac, France

- 57 ²⁸ Institut Hospitalo-Universitaire Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux
58 Université, Pessac, Bordeaux, France
59 ²⁹ INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, Bordeaux, France.
60 ³⁰ Department of Pediatric Emergency Care, Nantes University Hospital, F-44000, Nantes, France
61 ³¹ Obstetrical, Perinatal and Pediatric Epidemiology Research team, Center of Research in Epidemiology and
62 Statistics, Université de Paris, INSERM, F-75004, Paris, France.
63 ³² Inserm CIC 1413, Nantes University Hospital, F-44000, Nantes, France.
64 ³³ INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Sorbonne Université, Université de Paris, Paris,
65 France.
66 ³⁴ Hospices Civils de Lyon, Paediatric Nephrology, Rheumatology, Dermatology, Hopital Femme, Mère
67 Enfant, & Centre International de Recherche en Infectiologie / INSERM U1111, Bron, France
68 ³⁵ National Reference Center for Rheumatic and AutoImmune and Systemic Diseases in Children (RAISE),
69 Lyon, France
70 ³⁶ International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308,
71 ENS, UCBL, 69007 Lyon, France
72

73 [£] Complete lists of members of the “French Covid-19 Paediatric Inflammation Consortium” are provided in the
74 acknowledgment section

75 ^{*} Complete lists of members of the “French Pharmacovigilance network” are provided in the acknowledgment
76 section.

77
78
79

80 **Corresponding authors:**

81 Naïm Ouldali, MD, PhD, Department of General Pediatrics, Pediatric Infectious Disease and
82 Internal Medicine, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris,
83 F-75019 Paris, France Tel.: +33-1-40.03.20.48; Fax: +33-1-40.03.20.43; Email:
84 naim.ouldali@aphp.fr

85 Alexandre Belot, MD, PhD, Pediatric Nephrology, Rheumatology, Dermatology Unit, Hôpital
86 Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France. Tel: +33 427856481; Email:
87 alexandre.belot@chu-lyon.fr

88

89 **Word count:** abstract 359. MS 3357.

90 **Figure/Table count:** 0/3.

91 **Keywords:** COVID-19 mRNA vaccine, BNT162b2, multisystem inflammatory syndrome in
92 children, hyper-inflammatory syndrome, child, SARS-COV-2.

93
94

95 **Key points:**

96 **Question.** Is COVID-19 mRNA vaccine in 12-17-year-old children associated with subsequent
97 multisystemic hyper-inflammatory syndrome?

98 **Findings.** The French national pharmacovigilance system identified 9 children with a hyper-
99 inflammatory syndrome with multi-organ involvement following COVID-19 mRNA
100 vaccination (reporting rate 1.1 [0.5; 2.1] per 1,000,000 doses), of which only three had
101 evidence of previous SARS-CoV-2 infection. All cases fulfilled WHO definition for MIS-C, but
102 clinical and immunological features, along with short-term outcomes, slightly differed from
103 classical post SARS-CoV-2 MIS-C.

104 **Meaning.** Very rare cases of hyper-inflammatory syndrome can occur following COVID-19
105 mRNA vaccine in 12-17-year-old children. The very low rate of this entity, compared to
106 classical post-SARS-CoV-2 MIS-C, supports the benefit of SARS-CoV-2 vaccination in children.

107 **Abstract**

108

109 **Importance.** Multisystem inflammatory syndrome in children (MIS-C) is the most severe life-
110 threatening clinical entity associated with pediatric SARS-CoV-2 infection. Whether COVID-
111 19 mRNA vaccine can induce this complication in children is unknown.

112 **Objective.** To assess the risk of hyper-inflammatory syndrome following COVID-19 mRNA
113 vaccine in children.

114 **Design, Setting, and Participants.** Post-authorization national population-based surveillance
115 using the French enhanced pharmacovigilance surveillance system for COVID-19 vaccines. All
116 cases of suspected hyper-inflammatory syndrome following COVID-19 mRNA vaccine in 12–
117 17-year-old children between June 15th, 2021 and January 1st, 2022, were reported. Each
118 case was assessed for WHO MIS-C criteria. Causality assessment followed 2019 WHO
119 recommendations.

120 **Exposure.** COVID-19 mRNA vaccine.

121 **Main Outcome and Measures.** The main outcome was the reporting rate of post-vaccine
122 hyper-inflammatory syndrome per 1,000,000 COVID-19 mRNA vaccine doses in 12–17-year-
123 old children. This reporting rate was compared to the MIS-C rate per 1,000,000 12–17-year-
124 old children infected by SARS-CoV-2. Secondary outcomes included the comparison of
125 clinical features between post-vaccine hyper-inflammatory syndrome and post SARS-CoV-2
126 MIS-C.

127 **Results.** From June 2021 to January 2022, 8,113,058 COVID-19 mRNA vaccine doses were
128 administered to 4,079,234 12–17-year-old children. Among them, 9 presented a
129 multisystemic hyper-inflammatory syndrome. All cases fulfilled MIS-C WHO criteria. Main
130 clinical features included male predominance (8/9, 89%), cardiac involvement (8/9, 89%),
131 digestive symptoms (7/9, 78%), coagulopathy (5/9, 54%), cytolytic hepatitis (4/9, 46%), and
132 shock (3/9, 33%). 3/9 (33%) required intensive care unit transfer, and 2/9 (22%)
133 hemodynamic support. All cases recovered. Only three cases had evidence of previous SARS-
134 CoV-2 infection. The reporting rate was 1.1 (95%CI [0.5; 2.1]) per 1,000,000 doses injected.
135 As a comparison, 113 MIS-C (95%CI [95; 135]) occurred per 1,000,000 12–17-year-old
136 children infected by SARS-CoV-2. Clinical features (inflammatory parameters, cytopenia)
137 slightly differed from post-SARS-CoV-2 MIS-C, along with short-term outcomes (less PICU
138 transfer than MIS-C).

139 **Conclusion and Relevance.** Very few cases of hyper-inflammatory syndromes with multi-
140 organ involvement occurred following COVID-19 mRNA vaccine in 12–17-year-old children.
141 The low reporting rate of this syndrome, compared to the rate of MIS-C among same age
142 children infected by SARS-CoV-2, supports the benefit of SARS-CoV-2 vaccination in children.
143 Further studies are required to explore specific pathways of this entity compared to post-
144 SARS-CoV-2 MIS-C.
145
146

147 **Background.**

148 Multisystem inflammatory syndrome in children (MIS-C) is a novel clinical entity first
149 described in April 2020.¹⁻⁵ Its association with SARS-CoV-2 infection has been documented,
150 with a previous infection occurring 4 to 6 weeks before MIS-C onset.⁴⁻⁶ The main clinical
151 features of MIS-C are frequent acute cardiac dysfunction, shock, multi organ failure that
152 often require pediatric intensive care unit transfer and hemodynamic support.⁷ Thus,
153 numerous studies showed that MIS-C is by far the most severe form associated with SARS-
154 CoV-2 infection in children and the leading source of morbidity related to SARS-CoV-2 in this
155 age group.^{7,8}

156 The pathophysiology of this disease remains unknown, but previous investigations
157 showed that MIS-C is characterized by a cytokine storm⁹ associated with a superantigen-like
158 activation of T cells with an expansion of V β 21.3-expressing T cells which is not seen in toxic
159 shock syndrome, Kawasaki disease or other COVID-19 features¹⁰⁻¹³. Notably, SARS-CoV2
160 spike harbors a motif located in the receptor binding domain that is predicted *in silico* to
161 interact with V β region in T cells. Whether antigenic exposure limited to the Spike protein
162 can lead to similar dysregulated immune response remains unknown.

163 Two COVID-19 mRNA vaccines have been shown to be efficacious and well tolerated
164 in adults, and have been introduced since December 2020.¹⁴ Post-authorization studies
165 confirmed their major impact on SARS-CoV-2 epidemics,¹⁵ with very few serious adverse
166 events reported to date.^{16,17} In children, the immunogenicity, efficacy, as well as frequent
167 adverse events have been assessed in trials involving thousands of 12-17-year-old children.¹⁸
168 Based on these studies, the Food and Drug Administration (FDA) and European Medicines
169 Agency (EMA) authorized formulations of BNT162b2 COVID-19 vaccine for ages 12-17-year.
170 However, rare serious adverse events following immunization could not be detected by

171 these clinical trials. Especially, whether exposure to SARS-CoV-2 antigens due to mRNA
172 vaccine can induce MIS-C is unknown.

173 Given the lower burden of SARS-CoV-2 related diseases in children compared to
174 adults, elucidating the safety profile of mRNA vaccine, especially regarding MIS-C, is of
175 critical interest to establish its benefit-risk balance in this population. In this context,
176 monitoring post-vaccine MIS-C has been identified as a priority by the FDA, the EMA, and the
177 French National Agency for Medicines and Health Products safety (ANSM).¹⁹⁻²¹ Several cases
178 reports of children with MIS-C following mRNA vaccine recently raised major concerns
179 regarding this potential vaccine-related adverse event.²²⁻²⁵

180 Using a well-established national pharmacovigilance surveillance system coordinated
181 by ANSM,^{26,27} we aimed to evaluate the potential association of COVID-19 mRNA vaccine
182 and subsequent hyper-inflammatory syndrome in children.

183 **Methods.**

184 Ethical review.

185 For the pharmacovigilance surveillance system, this study was performed according to the
186 authorization from the National Commission on Informatics and Liberty (CNIL) n° 2014-302
187 for the national pharmacovigilance database done by ANSM. For the MIS-C following SARS-
188 CoV-2 infection surveillance system, the study was approved by the INSERM ethics
189 committee for evaluation (IRB00003888). A written information form validated by the ethics
190 committee was given to all participants. Oral consent was obtained from study participants;
191 no family members or participants refused to participate.

192

193 Study design and settings.

194 We conducted a post-authorization prospective national population-based
195 surveillance using the well-established ANSM pharmacovigilance system.^{26,27} This network is
196 based on 31 regional pharmacovigilance centers, which cover all the French territory, and is
197 coordinated by ANSM since 1973.²⁶ All ambulatory or hospital-based health practitioners
198 throughout France or patient that observe a suspected adverse drug reaction (ADR) report
199 the event to the regional center via a secure platform.²⁶ Reporting of all ADRs,
200 independently of the seriousness or expectedness, is compulsory for health practitioners. All
201 reports undergo a pharmacological, clinical and biological assessment process by a trained
202 assessor of the Regional Center. Cases are then registered in the national computerized
203 pharmacovigilance database, centralized at ANSM, to allow anonymized case reviewing at a
204 national level by ANSM and experts in the field, drug causality assessment, and to
205 recommend specific measures if required.²⁷ The detailed methodology of this French
206 pharmacovigilance system has been previously published.^{26,27}

207 As part of the national COVID-19 vaccination campaign, ANSM had put in place a
208 specific reinforced surveillance system to provide real-time monitoring of COVID-19 vaccines
209 ADRs at a national level.^{21,28} This is part of the risk management plan coordinated by the
210 European Medicines Agency (EMA). The objectives are to carry out a continuous assessment
211 of the safety of vaccines COVID-19 vaccines in order to confirm their safety or to quickly take
212 the relevant measures, and to allow the Health Ministry to adapt the vaccination strategy, if
213 necessary. For each marketed COVID-19 vaccine, two to five regional pharmacovigilance
214 centers have been designated to gather and assess on a daily basis all adverse drug reactions
215 reported following immunization. An expert of the organ involved is solicited to analyze the
216 reported cases every week, to identify atypical and/or serious patterns leading to potential
217 safety signals.²¹ Then a weekly meeting involving ANSM and all regional pharmacovigilance
218 centers is organized to discuss the expert pharmacovigilance reports, potential safety
219 signals, and new data from the literature, in order to confirm or not safety signals.^{21,28} A
220 complete report including the synopsis of these meeting are published by ANSM every two
221 weeks.^{21,28} If a national safety signal is validated, appropriate measures are issued in relation
222 with European Medicine Agency to prevent or reduce the likelihood of the risk occurring in
223 vaccinated people. The detailed methodology of this specific COVID-19 vaccine monitoring is
224 available elsewhere.^{21,28}

225

226 Cases review to assess WHO criteria for MIS-C and vaccine causality.

227 All pediatric cases of inflammatory syndrome, fever > 3 days, shock, or acute organ
228 dysfunction without any obvious cause, occurring any time after COVID-19 mRNA vaccine
229 injection in children under 18 years of age in France from June 15th, 2021, to January 1st,
230 2022, were eligible. Following 2019 WHO guidelines for causality assessment of an adverse

231 event following immunization,²⁹ each case was reviewed by a multidisciplinary committee,
232 with experts in pediatric immunization, pediatric infectious diseases, pediatric
233 rheumatology, immunology and internal medicine, pediatric intensive care, pediatric
234 cardiology, and experts pharmacologists from pharmacovigilance centers. All these experts
235 were involved in MIS-C surveillance and management in France as part of the French MIS-C
236 consortium, and developed specific expertise in this field.^{5,30,31} Medical records were
237 obtained for all cases to accurately assess if cases fulfilled WHO criteria for MIS-C. Cases
238 were included after reviewing if they fulfilled WHO MIS-C criteria, with a delay between the
239 last vaccine administration and disease onset < 2 months, based on available data from the
240 literature regarding the delay between SARS-CoV-2 infection and MIS-C onset.⁴⁻⁶ An
241 important part of the vaccine causality assessment relied on identifying other potential
242 causes for the event.²⁹ For hyper-inflammatory syndrome, extensive investigation of
243 previous exposure to SARS-CoV-2 over the past two months was critical, and relied on
244 investigating history of documented infection, and performing nasopharyngeal SARS-CoV-2
245 Polymerase chain reaction (PCR) and anti-Nucleocapsid (anti-N) serology.³²

246

247 National immunization program.

248 BNT162b2 COVID-19 mRNA vaccine have been introduced for 12-17-year-old children
249 on June 15th, 2021 in France.³³ It has been followed by mRNA-1273 approval for same age
250 children on July, 27th, 2021.³³ A higher risk of myocarditis or pericarditis has been suggested
251 following mRNA-1273 compared to BNT162b2 in adults younger than 30 years old.³⁴ This has
252 led French authorities to prioritize BNT162b2 for 12-17-year-old children immunization.
253 Thus, by January 1st, 2022, the large majority of vaccinated 12-17-year-old children received
254 BNT162b2 (>95%).³¹

255

256 Outcome measure.

257 The main outcome was the national reporting rate of hyper-inflammatory syndrome
258 following COVID-19 mRNA vaccine per 1,000,000 doses in 12-17-year-old children in France.
259 To calculate national reporting rate, we used as a denominator the total number of COVID-
260 19 mRNA vaccine dose administered in 12-17-year-old children over the study period
261 (available at [https://solidarites-sante.gouv.fr/grands-dossiers/vaccin-covid-19/article/le-](https://solidarites-sante.gouv.fr/grands-dossiers/vaccin-covid-19/article/le-tableau-de-bord-de-la-vaccination)
262 [tableau-de-bord-de-la-vaccination](https://solidarites-sante.gouv.fr/grands-dossiers/vaccin-covid-19/article/le-tableau-de-bord-de-la-vaccination)). We also estimated in the same age-group, in the same
263 population, the rate of post-SARS-CoV-2 MIS-C cases per 1,000,000 infections in 12-17-year-
264 old children in France for comparison.

265 Secondary outcomes were the reporting rate of hyper-inflammatory syndrome following
266 first and second injections of COVID-19 mRNA vaccine in 12-17-year-old children in France,
267 reporting rate by sex, and comparison of clinical features of hyper-inflammatory syndrome
268 following COVID-19 mRNA vaccine versus post-SARS-CoV-2 MIS-C cases.

269

270 MIS-C following SARS-CoV-2 infection surveillance system.

271 To estimate the rate of post-SARS-CoV-2 MIS-C cases per 1,000,000 infections in 12-
272 17-year-old children in France, we used data from the French COVID-19 Pediatric
273 Inflammation Consortium, coordinated by Public health France.^{5,30,31} As previously
274 published, since April 2020, all suspected MIS-C cases in France were mandatorily reported
275 to Public health France. Each suspected case was then assessed following WHO criteria for
276 MIS-C.^{5,30,31} Furthermore, Public health France also conducted seroprevalence studies that
277 allowed estimating the proportion of 12-17-year-old old children infected by SARS-CoV-2
278 since the beginning of the pandemic.³⁵ Thus, to estimate the rate of post-SARS-CoV-2 MIS-C

279 cases per 1,000,000 infections, we used as a numerator the number of confirmed 12-17-
280 year-old MIS-C cases reported to Public health France since the start of the pandemic, and as
281 a denominator the estimated number of 12-17-year-old French children infected by SARS-
282 CoV-2 since the start of the pandemic. To avoid any bias in MIS-C rate estimation due to
283 vaccine implementation,³¹ we restricted this analysis to the pre-vaccine period, i.e. from the
284 start of the pandemic to June 15th, 2021.

285 This surveillance system also collected clinico-biological and short term outcome data
286 of MIS-C cases that fulfilled WHO criteria.^{5,30,31} Thus, to compare the clinical presentation of
287 hyper-inflammatory syndrome following COVID-19 mRNA vaccine to post-SARS-CoV-2 MIS-C
288 cases in the same population, we included all unvaccinated 12-17-year-old MIS-C cases
289 fulfilling WHO criteria with available clinical files as same-age and same-population
290 comparator group.

291

292 Statistical analysis.

293 We describe patient characteristics with numbers (percentages) for categorical
294 variables and median (interquartile range [IQR]) for quantitative variables. We compared
295 clinical and biological characteristics using non-parametric Fisher's exact test for categorical
296 variables and Mann-Whitney U test for quantitative variables. A two-sided p-value <0.05 was
297 considered statistically significant. Reporting rate of hyper-inflammatory syndrome was
298 expressed as cases per 1,000,000 vaccine injections with 95% CIs. All statistical analyses
299 involved using R v3.6.1 (<http://www.R-project.org>).

300

301 **Results.**

302 From June 15th, 2021 to January 1st, 2022, 8,113,058 COVID-19 mRNA vaccine doses
303 were administered to 4,079,234 12-17-year-old children in France (including 4,079,234 first
304 injections, 3,905,636 second injections, and 128,188 third injections). Over this period, 2,028
305 adverse drug reactions related to COVID-19 mRNA vaccine have been reported to the
306 pharmacovigilance centers in 12-17-year-old children. Among them, 9 cases of hyper-
307 inflammatory syndrome were reported. All cases fulfilled WHO criteria for MIS-C (Table 1).
308 All cases involved BNT162b2 vaccine (5 cases following the first injection, 4 following the
309 second injection). The delay between last injection and disease onset ranged from 2 days to
310 42 days.

311

312 Investigation of previous SARS-CoV-2 infection.

313 All 9 cases had complete data for history of documented infection, nasopharyngeal SARS-
314 CoV-2 PCR, and anti-N serology. In one case, a previous infection 7 months before disease
315 onset was reported, but was too far apart to be considered as linked to the disease. All
316 children had negative SARS-CoV-2 PCR, and three children had a positive anti-N serology
317 (Table 1). Based on all information available, the mRNA vaccine causality was considered
318 consistent in 4 cases, and indeterminate in 5 cases (details Table 1 and Appendix 1).

319

320 National reporting rate of hyper-inflammatory syndrome following mRNA vaccine

321 Considering all 9 cases of hyper-inflammatory syndrome, a national reporting rate of 1.1
322 (95% CI [0.5; 2.1]) per 1,000,000 mRNA vaccine doses administered in 12-17-year-old
323 children was observed. Excluding cases for which evidence of previous SARS-CoV-2 infection
324 has been found, the reporting rate was reduced to 0.7 (95% CI [0.3; 1.6]) per 1,000,000

325 mRNA vaccine doses administered. This reporting rate varied from 1.2 (95% CI [0.4; 2.9])
326 following the first mRNA vaccine injection to 1.0 (95% CI [0.3; 2.6]) after the second mRNA
327 vaccine injection (Table 2). The reporting rate was significantly higher for males compared to
328 females (1.9 [0.8; 3.8] versus 0.3 [0.0; 1.4] per 1,000,000 doses, respectively, $p=0.039$).

329 As a comparator, 130 post-SARS-CoV-2 MIS-C cases occurred in 12-17-year-old children, for
330 1,148,299 same-age children infected by SARS-CoV-2, leading to a MIS-C rate of 113.3 [94.7;
331 134.6] per 1,000,000 12-17-year-old infected children (Table 2).

332

333 Clinical features of hyper-inflammatory syndrome following COVID-19 mRNA vaccine
334 compared to post-SARS-CoV-2 MIS-C cases

335 The detailed clinical presentation of children with hyper-inflammatory syndrome following
336 COVID-19 mRNA vaccine is provided Table 1. Median age was 12.5 years (IQR [12.0; 13.5]),
337 8/9 (89%) children were male and 3/8 had comorbidities (one type 1 diabetes, one
338 osteochondritis with overweight, and one leukemia in remission). The most frequent clinical
339 features were cardiac involvement (8/9, 89%, including 7 elevated cardiac enzymes, 4
340 pericarditis, 3 acute left ventricular ejection fraction decrease $\leq 55\%$, 1 transient coronary
341 dilation and 1 myocarditis), gastrointestinal symptoms (7/9, 78%), coagulopathy (5/9, 56%),
342 mucocutaneous involvement (5/9, 56%), cytolytic hepatitis (4/9, 44%) and shock (3/9, 33%).
343 Macrophage activation syndrome was identified in one case. For comparison, among 199
344 children with post-SARS-CoV-2 MIS-C, 108 (54%) were male ($p=0.081$), and cardiac
345 involvement was found in 63% ($p=0.16$, Table 3).

346 Some biological parameters differed between post-vaccine hyper-inflammatory syndrome
347 and post-SARS-CoV-2 MIS-C, including inflammatory parameters (median CRP level 186 [97;
348 250] vs 271 [187; 354], respectively, $p=0.031$), and blood cell count (median hemoglobin

349 12.3 [11.6; 13.6] vs 11.0 [10.1; 11.0], respectively, $p=0.022$, Table 3). Of note, 2/9 (22%)
350 children with post-vaccine hyper-inflammatory syndrome had a transient hypereosinophilia
351 (compared to 9/199 (5%) in post-SARS-CoV-2 MIS-C). These two children were explored for
352 TRBV11-2/Vb21.3 expansion, none of them had an expansion of this repertory, while it was
353 present in 75% of post-SARS-CoV-2 MIS-C patients¹¹.

354

355 Specific therapy and short-term outcomes.

356 Short term outcomes seemed also less severe for post-vaccine hyper-inflammatory
357 syndrome, with a lower rate of PICU transfer (3/9, 33%), compared to 143/199 (72%) for
358 post-SARS-CoV-2 MIS-C ($p=0.022$, Table 3). Six children were treated by an association of
359 intravenous immunoglobulins plus methylprednisolone, of whom one received a subsequent
360 10mg/kg/day methylprednisolone pulse. Two children received methylprednisolone alone,
361 and one did not receive specific immunomodulator agent. All children fully recovered at the
362 time of discharge. Median length of hospital stay was 7 days (IQR [7; 9]).

363

364 **Discussion.**

365 To our knowledge, this is the first post-authorization population-based
366 pharmacovigilance study assessing the risk of hyper-inflammatory syndrome following
367 COVID-19 mRNA vaccine in 12-17-year-old children. We found that this entity was observed
368 with an reporting rate of 1.1 (95% CI [0.5; 2.1]) per 1,000,000 doses in this population. In
369 most cases, no evidence of previous SARS-CoV-2 infection was observed, suggesting a link
370 between this entity and COVID-19 mRNA vaccine. This rare serious adverse event should be
371 put in balance with the rate of post-SARS-CoV-2 MIS-C in the same age group in the same
372 population, which was 100-fold higher. A recent study highlighted that COVID-19 mRNA
373 vaccine may significantly reduce the incidence of post-SARS-CoV-2 MIS-C (Hazard Ratio 0.09
374 (95% CI, 0.04-0.21)).³¹ Taken together, these findings suggest that the benefit-risk balance of
375 COVID-19 mRNA vaccine is largely in favor of the vaccination in this age group, in a context
376 of active circulation of SARS-CoV-2.

377 An important issue is to delineate the clinical spectrum of this entity, which may have
378 overlap with several other diseases. First, cases of myocarditis have been reported following
379 COVID-19 mRNA vaccines, especially in young men.^{36,37} These cases mainly occurred after
380 the second dose of vaccine, few days after the injection, and were rapidly resolute in most
381 cases.^{36,37} The higher rate of hyper-inflammatory syndrome following COVID-19 mRNA
382 vaccine in males, and the rate of cardiac involvement (8/9 cases) suggest similitudes with
383 this entity. However, myocarditis were classically afebrile, with low inflammatory
384 parameters, and were a mono-organ involvement.³⁷ These major clinical differences may
385 allow distinguishing these two entities. Second, all cases of hyper-inflammatory syndrome
386 following COVID-19 mRNA vaccine fulfilled WHO definition for MIS-C. Indeed, the prolonged
387 hyper-inflammatory state, the multi-organ involvement and the severity of the disease are

388 principal features of these two entities,⁷ indicating at least a major overlap. However, if
389 statistical comparison between these two diseases was limited by the low number of cases,
390 our findings suggest that post-SARS-CoV-2 MIS-C may have still higher inflammatory
391 parameters, and more cytopenia. This may be in line with the significantly lower rate of PICU
392 transfer (33% vs 72%) for hyper-inflammatory syndrome following COVID-19 mRNA vaccine
393 cases, which might reflect a less severe immune storm and disease course. Notably, a 4-
394 week delay has been observed in the context of MIS-C following SARS-CoV-2 infection³⁸⁻⁴⁰.
395 Here, the delay from first antigen exposure to hyper-inflammatory syndrome occurred
396 within a week in 3 patients and after 4-12 weeks in the 6 others. In the cases with early
397 reaction, a hypereosinophilia was seen in 2 patients, a feature not seen in classical MIS-C.
398 This observation might reflect immunoallergic reaction distinct from the superantigenic like
399 features of MIS-C. Expansion of Vb21.3 expressing T cells is a hallmark of the MIS-C and can
400 be easily assessed by flowcytometry.¹¹ By contrast, the two children with post-vaccination
401 hyper-inflammatory syndrome had no expansion of this T cell subset. Taken together, these
402 clinical and immunological divergences may imply distinct underlying pathways and further
403 studies are required to expand this finding. Third, a recent study coordinated by the CDC
404 reported cases of multisystem inflammatory system in adults (MIS-A) in USA, in vaccinated
405 and unvaccinated adults.³² Twenty cases were identified, of whom seven were vaccinated.
406 However, all of them had a documented previous exposure to SARS-CoV-2, questioning the
407 direct causal role of mRNA vaccines in these manifestations, and diverging with the pediatric
408 syndrome reported here, with only 2/9 patients presenting a seropositivity to N antigen. The
409 issue of delineating these different entities underline the need to extensively investigate
410 cases of hyper-inflammatory syndromes following mRNA vaccines, especially by performing
411 anti-S and anti-N serology, along with exploration for TRBV11-2/Vb21.3 expansion.

412 Because this hyper-inflammatory syndrome following COVID-19 mRNA vaccine was
413 severe with acute multi-organ dysfunction, therapeutic aspects are of major interest. In this
414 cohort, most children were treated by an association of immunoglobulins plus
415 methylprednisolone, following MIS-C therapeutic protocols.³⁰ Only one child treated with
416 this combination required a therapeutic escalation, and received a methylprednisolone pulse
417 (10mg/kg/day). All children fully recovered. If sample size precludes any definitive
418 conclusion, these findings suggest that the association of immunoglobulins plus
419 methylprednisolone may be a suitable approach while awaiting more evidence regarding
420 these treatments.

421

422 Several limitations should be discussed. First the causality of COVID-19 mRNA
423 vaccines assessment was mainly based on investigation for previous SARS-CoV-2 infection.
424 However, pauci or asymptomatic infections are frequent in children, and may not have been
425 documented. Furthermore, false negatives can be observed for anti-Nucleocapsid serology.⁴¹
426 Thus, we cannot exclude that some of the cases reported here could be related to
427 undiagnosed SARS-CoV-2 infections. Second, because this entity has not been previously
428 described in healthy populations, we could not have a control population to estimate the
429 expected incidence of this disease in unvaccinated children, which would help in elucidating
430 the vaccine causality.¹⁶ Third, we cannot rule out under reporting of adverse drug events in
431 our population, which may have biased the estimated rate of hyper-inflammatory syndrome.
432 However, following the implementation of COVID-19 mRNA vaccine, a major effort has been
433 made by all pharmacovigilance centers to publicize that the reporting of any suspected
434 adverse drug reaction following these vaccines was mandatory.²⁶ The impressive number of
435 suspected adverse drug reaction reports (>80,000 between January 2021 and January 2022

436 in France) suggest that underreporting may have been very rare, especially for serious
437 adverse drug reactions.²⁶ Fourth, given the very low proportion of 12-17-year-old children
438 vaccinated by mRNA-1273 (<5%), we could not conduct subgroup analysis to compare the
439 risk of hyper-inflammatory syndromes according to COVID-19 mRNA vaccine type. Further
440 studies are required to explore if this risk differ between BNT162b2 and mRNA-1273. Fifth,
441 because mRNA vaccines were only recommended to 12-17-year-old children in France until
442 December 2021, we could not explore the risk of hyper-inflammatory syndrome in younger
443 children.

444

445 **Conclusion.**

446 In this study, we identified cases of hyper-inflammatory syndrome following COVID-19
447 mRNA vaccines in 12-17-year-old children in France. This syndrome was very rare, and its
448 reporting rate, in comparison with the rate of MIS-C following SARS-CoV-2 infection in the
449 same age-group, largely supports the vaccination in a context of an important circulation of
450 SARS-CoV-2. This syndrome shared many clinical features with post-SARS-CoV-2 MIS-C, but
451 some clinical, immunological and short-term outcomes divergences call for further studies to
452 explore its specific pathway.

453

454 **Author Contributions:**

455 NO, HB, FA, and AB made substantial contributions to the conception or design of the work.
456 NO and AB drafted the manuscript. NO, HB, CLeb, CLev, EJ, BBM, CO, SR, VH, IKP, ND, LDP,
457 XI, CGLG, FA and AB were involved in the acquisition, analysis, or interpretation of data. All
458 authors provided critical revision of the manuscript for important intellectual content. NO
459 and HB had full access to all data in the study and take responsibility for the integrity of the
460 data and the accuracy of the data analysis.

461

462 **Funding/Support:** NO was supported by the 2021 ESPID (European Society for Pediatric
463 Infectious Diseases) Fellowship Award. the French Covid-19 Paediatric Inflammation
464 Consortium received an unrestricted grant from the Square Foundation (Grandir–Fonds de
465 Solidarité Pour L'enfance).

466

467 **Conflicts of Interest Disclosures:** NO reports travel grants from GSK, Pfizer, and Sanofi. Dr
468 Javouhey reported receiving grants from CSL Behring. Dr C. Levy reported receiving grants
469 from GlaxoSmithKline, Merck Sharp & Dohme, and Sanofi and personal fees from Pfizer and
470 Merck. Dr Cohen reported receiving personal fees from GlaxoSmithKline, Pfizer, Sanofi, and
471 Merck Sharp & Dohme. All other authors have no potential conflicts of interest to disclose.

472

473 **Role of the Funder/Sponsor:** The funders had no role in the design or conduct of the study,
474 collection management, analysis, or interpretation of the data; preparation, review, or
475 approval of the manuscript; or the decision to submit the manuscript for publication.

476

477 **Additional Contributions :** We are grateful to Agence Nationale de Sécurité du Médicament
478 et des produits de santé (ANSM), Santé Publique France, Société Française de Pédiatrie,
479 Groupe de Pédiatrie Générale, Groupe de Pathologie Infectieuse Pédiatrique, Groupe
480 Francophone de Réanimation et d'Urgences Pédiatriques, Société Française de Cardiologie,
481 Filiale de Cardiologie Pédiatrique et Congénitale, Société Francophone Dédiée à L'étude des
482 Maladies Inflammatoires Pédiatriques, and Filière de Santé des Maladies Auto-immunes et
483 Auto-inflammatoires Rares for their participation in the French Covid-19 Paediatric
484 Inflammation Consortium study. We thank Youssef Shaim, Laurence Baril, Mehdi Benkebil,
485 Samuel Crommelynck, Baptiste Jacquot from ANSM, Isabelle Ramay, BSc, Claire Prieur, BSc,

486 Marine Borg, Aurore Prieur, BSc, Laura Meyet, LLM, Jérémy Levy, BSc, Stéphane Bechet,
487 MSc, and Sofia Abbou, LLM, from ACTIV (Association Clinique et Thérapeutique Infantile du
488 Val-de-Marne), Créteil, France; Cecile Hoffart, MSc, and Maxime Brussieux, BSc, from Clinical
489 Research Centre, Centre Hospitalier Intercommunal de Créteil, Créteil, France; Daniel Levy-
490 Bruhl, MD, Mireille Allemand, Scarlett Georges, BSc, Valerie Olie, PhD, Nolween Regnault,
491 PhD, and Jerome Naud, PharmD, from Santé Publique France, Agence Nationale de Santé
492 Publique, Saint-Maurice; Murielle Herasse, PhD, from Filière de Santé Des Maladies Auto-
493 immunes et Auto-inflammatoires Rares (FAI2R), Lyon, France; and David Skurnik, PhD, from
494 INSERM U1151-Equipe 11. We are grateful to every microbiological laboratory staff member
495 who performed severe acute respiratory syndrome coronavirus 2 reverse transcriptase-
496 polymerase chain reaction and antibody testing in each center. None of the persons listed
497 here received compensation for their role in the study.

498

499 In addition to the authors, the following collaborators participated to the “French Covid-19 Pediatric
500 Inflammation Consortium”

501 Maelle Selegny (Amiens); Lucas Jeusset, Aurelie Donzeau, Sophie Lety, Bertrand Leboucher (Angers);
502 Agnes Baur (Annecy); Cristian Fedorczuk (Arcachon); Marion Lajus, Philippe Bensaid (Argenteuil);
503 Yacine Laoudi (Aulnay Sous Bois); Charlotte Pons (Avignon); Anne-Cécile Robert, Camille Beaucourt
504 (Besançon); Loïc De Pontual (Bondy); Muriel Richard, Etienne Goisque, Xavier Iriart, Olivier Brissaud,
505 Pierre Segretin, Julie Molimard (Bordeaux); Marie-Clothilde Orecel, Gregoire Benoit (Boulognes
506 Billancourt); Lucille Bongiovanni (Brest); Guerder Margaux, Robin Pouyau, Jean-Marie De Guillebon
507 De Resnes, Ellia Mezgueldi, Fleur Cour-Andlauer, Come Horvat, Pierre Poinot, Cecile Frachette,
508 Antoine Ouziel, Yves Gillet (Bron); Catherine Barrey (Bry Sur Marne); Jacques Brouard, Florence
509 Villedieu (Caen); Vathanaksambath Ro, Narcisse Elanga (Cayenne); Vincent Gajdos (Clamart); Romain
510 Basmaci (Colombes); Hadile Mutar (Contamine sur Arve); Sébastien Rouget (Corbeil Essone); Elodie
511 Nattes, Isabelle Hau, Sandra Biscardi, El Jurdi Houmam, Camille Jung (Créteil); Denis Semama,
512 Frederic Huet (Dijon); Anne-Marie Zoccarato (Gap); Mayssa Sarakbi (Gonnesse); Guillaume
513 Mortamet, Cécile Bost-Bru (Grenoble); Joachim Bassil (Laval); Caroline Vinit, Véronique Hentgen (Le
514 Chesnay); Pascal Leroux, Valérie Bertrand, Caroline Parrod (Le Havre); Irina Craiu, Isabelle Kone-Paut,
515 Philippe Durand, Pierre Tissiere, Caroline Claude, Guillaume Morelle, Tamazoust Guiddir, Charlotte
516 Borocco (Le Kremlin-Bicêtre); Frédérique Delion (Les Abymes); Camille Guillot, Stéphane Leteurtre,
517 François Dubos, Mylene Jouancastay, Alain Martinot, Valentine Voeusler (Lilles); Jane Languépin
518 (Limoges); Nathalie Garrec, Arnaud Chalvon Demersay (Marne La Vallée); Aurélie Morand,

519 Emmanuelle Bosdure, Noémie Vanel, Fabrice Ughetto, Fabrice Michel (Marseille); Caujolle Marie,
520 Renaud Blonde, Jacqueline Nguyen (Mayotte); Olivier Vignaud, Caroline Masserot-Lureau, François
521 Gouraud, Carine Araujo (Meaux); Tara Ingrao (Metz); Sanaa Naji (Mont de Marsans); Mohammed
522 Sehaba (Montargis); Christine Roche (Montbrison); Aurelia Carbasse, Christophe Milesi (Montpellier);
523 Mustapha Mazeghrane (Montreuil); Sandrine Haupt (Mulhouse); Cyril Schweitzer (Nancy); Benedicte
524 Romefort, Elise Launay, Christèle Gras-Le Guen (Nantes); Ahmed Ali, Nathalie Blot (Neuilly Sur Seine);
525 Antoine Tran, Anne Rancurel, Mickael Afanetti (Nice); Sophie Odorico (Nîmes); Deborah Talmud
526 (Orléans); Anais Chosidow, Anne-Sophie Romain, Emmanuel Grimprel Marie Pouletty, Jean
527 Gaschignard, Olivier Corseri, Albert Faye, Jean Gaschignard, Isabelle Melki, Camille Ducrocq, Cherine
528 Benzoid, Johanna Lokmer, Stéphane Dager, Maryline Chomton, Anna Deho, Fleur Lebourgeois,
529 Sylvain Renolleau, Fabrice Lesage, Florence Moulin, Laurent Dupic, Yael Pinhas, Agathe Debray,
530 Martin Chalumeau, Véronique Abadie, Pierre Frange, Jeremie F Cohen, Slimane Allali, William Curtis,
531 Zahra Belhadjer, Johanne Auriau, Mathilde Méot, Lucile Houyel, Damien Bonnet, Christophe
532 Delacourt, Brigitte Bader Meunier, Pierre Quartier, Youssef Shaim, Laurence Baril, Samuel
533 Crommelynck, Baptiste Jacquot (Paris); Philippe Blanc (Poissy); Natacha Maledon (Poitiers); Blandine
534 Robert (Pontoise); Camille Loeile (Quimper); Clémence Cazau, Gauthier Loron (Reims); Simona Gaga
535 (Remiremont); Cécile Vittot, Loubna El Nabhani (Rouen); François Buisson (Saumur); Muriel Prudent
536 (Sens); Hugues Flodrops (St Denis, La Réunion); Fadhila Mokraoui, Simon Escoda (St Denis); Nina
537 Deschamps (St Malot); Laurent Bonnemains, Sarah-Louisa Mahi, Clara Mertes, Joelle Terzic, Julie
538 Helms (Strasbourg); Charlotte Idier (Tours); Soraya Chenichene, Nicoleta Magdolena Ursulescu
539 (Trévenans); Gladys Beaujour (Villeneuve Saint Georges).

540

541 In addition to the authors, the following collaborators participated to the “French Pharmacovigilance
542 network”:

543 Anaïs Gaiffe (Besançon), Antoine Pariente, Francesco Salvo (Bordeaux), Joelle Micallef (Marseille),
544 Martine Tebacher (Strasbourg), Haleh Bagheri (Toulouse), Marie-Sarah Agier (Tours).

545

546 **References.**

- 547 1. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P.
548 Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet*. Published online
549 May 7, 2020. doi:10.1016/S0140-6736(20)31094-1
- 550 2. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in
551 Children in New York State. *N Engl J Med*. 2020;383(4):347-358.
552 doi:10.1056/NEJMoa2021756
- 553 3. Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a
554 Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.
555 *JAMA*. 2020;324(3):259-269. doi:10.1001/jama.2020.10369
- 556 4. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S.
557 Children and Adolescents. *N Engl J Med*. 2020;383(4):334-346. doi:10.1056/NEJMoa2021680
- 558 5. Belot A, Levy-Bruhl D, French Covid-19 Pediatric Inflammation Consortium.
559 Multisystem Inflammatory Syndrome in Children in the United States. *N Engl J Med*.
560 2020;383(18):1793-1794. doi:10.1056/NEJMc2026136
- 561 6. Belay ED, Abrams J, Oster ME, et al. Trends in Geographic and Temporal Distribution
562 of US Children With Multisystem Inflammatory Syndrome During the COVID-19 Pandemic.
563 *JAMA Pediatr*. 2021;175(8):837-845. doi:10.1001/jamapediatrics.2021.0630
- 564 7. Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in
565 children and adolescents. *Lancet Infect Dis*. 2020;20(11):e276-e288. doi:10.1016/S1473-
566 3099(20)30651-4
- 567 8. Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and Outcomes of US
568 Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C)
569 Compared With Severe Acute COVID-19. *JAMA*. 2021;325(11):1074-1087.
570 doi:10.1001/jama.2021.2091
- 571 9. Consiglio CR, Cotugno N, Sardh F, et al. The Immunology of Multisystem
572 Inflammatory Syndrome in Children with COVID-19. *Cell*. 2020;183(4):968-981.e7.
573 doi:10.1016/j.cell.2020.09.016
- 574 10. Hoste L, Roels L, Naesens L, et al. TIM3+ TRBV11-2 T cells and IFN γ signature in
575 patrolling monocytes and CD16+ NK cells delineate MIS-C. *J Exp Med*.
576 2022;219(2):e20211381. doi:10.1084/jem.20211381
- 577 11. Moreews M, Le Gouge K, Khaldi-Plassart S, et al. Polyclonal expansion of TCR Vbeta
578 21.3+ CD4+ and CD8+ T cells is a hallmark of Multisystem Inflammatory Syndrome in
579 Children. *Sci Immunol*. 2021;6(59):eabh1516. doi:10.1126/sciimmunol.abh1516
- 580 12. Porritt RA, Paschold L, Noval Rivas M, et al. HLA class I-associated expansion of
581 TRBV11-2 T cells in Multisystem Inflammatory Syndrome in Children. *J Clin Invest*. Published
582 online March 11, 2021. doi:10.1172/JCI146614
- 583 13. Ramaswamy A, Brodsky NN, Sumida TS, et al. Immune dysregulation and
584 autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem
585 inflammatory syndrome in children. *Immunity*. Published online April 13, 2021.
586 doi:10.1016/j.immuni.2021.04.003
- 587 14. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
588 Covid-19 Vaccine. *N Engl J Med*. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
- 589 15. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide
590 Mass Vaccination Setting. *N Engl J Med*. 2021;384(15):1412-1423.
591 doi:10.1056/NEJMoa2101765

- 592 16. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19
593 Vaccine in a Nationwide Setting. *N Engl J Med*. 2021;385(12):1078-1090.
594 doi:10.1056/NEJMoa2110475
- 595 17. Simone A, Herald J, Chen A, et al. Acute Myocarditis Following COVID-19 mRNA
596 Vaccination in Adults Aged 18 Years or Older. *JAMA Internal Medicine*. 2021;181(12):1668-
597 1670. doi:10.1001/jamainternmed.2021.5511
- 598 18. Frenck RW, Klein NP, Kitchin N, et al. Safety, Immunogenicity, and Efficacy of the
599 BNT162b2 Covid-19 Vaccine in Adolescents. *N Engl J Med*. Published online May 27,
600 2021:NEJMoa2107456. doi:10.1056/NEJMoa2107456
- 601 19. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk
602 Assessment Committee (PRAC) 30 August – 2 September 2021. European Medicines Agency.
603 Published 2021. Accessed December 27, 2021.
604 [https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-](https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-30-august-2-september-2021)
605 [assessment-committee-prac-30-august-2-september-2021](https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-30-august-2-september-2021)
- 606 20. FDA. Food and Drug Administration. COVID-19 vaccines. *FDA*. Published online 2021.
607 Accessed December 27, 2021. [https://www.fda.gov/emergency-preparedness-and-](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines)
608 [response/coronavirus-disease-2019-covid-19/covid-19-vaccines](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines)
- 609 21. Lacroix C, Salvo F, Gras-Champel V, et al. French organization for the
610 pharmacovigilance of COVID-19 vaccines: A major challenge. *Therapie*. 2021;76(4):297-303.
611 doi:10.1016/j.therap.2021.05.003
- 612 22. Abdelgalil AA, Saeedi FA. Multisystem Inflammatory Syndrome in a 12-Year-old Boy
613 After mRNA-SARS-CoV-2 Vaccination. *Pediatr Infect Dis J*. Published online December 21,
614 2021. doi:10.1097/INF.0000000000003442
- 615 23. DeJong J, Sainato R, Forouhar M, Robinson D, Kunz A. Multisystem Inflammatory
616 Syndrome in a Previously Vaccinated Adolescent Female With Sickle Cell Disease. *Pediatr*
617 *Infect Dis J*. Published online December 21, 2021. doi:10.1097/INF.0000000000003444
- 618 24. Yalcinkaya R, Oz FN, Polat M, et al. A Case of Multisystem Inflammatory Syndrome in
619 a 12-year-old Male After COVID-19 mRNA Vaccine. *Pediatr Infect Dis J*. Published online
620 December 14, 2021. doi:10.1097/INF.0000000000003432
- 621 25. Danish Medicine Agency. Danish Medicines Agency investigates a case of
622 inflammatory condition reported after COVID-19 vaccination. Danish Medicines Agency.
623 Published 2021. Accessed January 4, 2022.
624 [https://laegemiddelstyrelsen.dk/en/news/2021/danish-medicines-agency-investigates-a-](https://laegemiddelstyrelsen.dk/en/news/2021/danish-medicines-agency-investigates-a-case-of-inflammatory-condition-reported-after-covid-19-vaccination/)
625 [case-of-inflammatory-condition-reported-after-covid-19-vaccination/](https://laegemiddelstyrelsen.dk/en/news/2021/danish-medicines-agency-investigates-a-case-of-inflammatory-condition-reported-after-covid-19-vaccination/)
- 626 26. Lacroix C, Mallaret M, Jonville-Bera AP. Pharmacovigilance and drug-induced rare
627 diseases: Strengths of the French Network of Regional Pharmacovigilance Centres. *Therapie*.
628 2020;75(2):207-213. doi:10.1016/j.therap.2020.02.012
- 629 27. Abou Taam M, Jacquot B, Ferard C, et al. The French pharmacovigilance surveys: A
630 French distinctiveness, a real input. *Therapie*. 2021;76(5):441-447.
631 doi:10.1016/j.therap.2020.05.011
- 632 28. Benkebil M, Gautier S, Gras-Champel V, Massy N, Micallef J, Valnet Rabier MB.
633 COVID-19 vaccines surveillance in France: a global response to a major national challenge.
634 *Anaesth Crit Care Pain Med*. 2021;40(3):100866. doi:10.1016/j.accpm.2021.100866
- 635 29. Causality assessment of an adverse event following immunization (AEFI): user manual
636 for the revised WHO classification, 2nd ed., 2019 update. Accessed January 1, 2022.
637 [https://www.who.int/publications-detail-redirect/causality-assessment-aefi-user-manual-](https://www.who.int/publications-detail-redirect/causality-assessment-aefi-user-manual-2019)
638 [2019](https://www.who.int/publications-detail-redirect/causality-assessment-aefi-user-manual-2019)

- 639 30. Ouldali N, Toubiana J, Antona D, et al. Association of Intravenous Immunoglobulins
640 Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem
641 Inflammatory Syndrome in Children. *JAMA*. 2021;325(9):855-864.
642 doi:10.1001/jama.2021.0694
- 643 31. Levy M, Recher M, Hubert H, et al. Multisystem Inflammatory Syndrome in Children
644 by COVID-19 Vaccination Status of Adolescents in France. *JAMA*. Published online December
645 20, 2021. doi:10.1001/jama.2021.23262
- 646 32. Belay ED, Godfred Cato S, Rao AK, et al. Multisystem Inflammatory Syndrome in
647 Adults after SARS-CoV-2 infection and COVID-19 vaccination. *Clin Infect Dis*. Published online
648 November 28, 2021:ciab936. doi:10.1093/cid/ciab936
- 649 33. Haute autorité de Santé. French SARS-CoV-2 immunization program. Haute Autorité
650 de Santé. Published 2021. Accessed December 27, 2021. [https://www.has-](https://www.has-sante.fr/jcms/p_3178533/fr/vaccination-dans-le-cadre-de-la-covid-19)
651 [sante.fr/jcms/p_3178533/fr/vaccination-dans-le-cadre-de-la-covid-19](https://www.has-sante.fr/jcms/p_3178533/fr/vaccination-dans-le-cadre-de-la-covid-19)
- 652 34. Le Vu S, Bertrand M, Jabagi MN, et al. Myocardite et péricardite après la vaccination
653 Covid-19. EPI-PHARE. Published November 8, 2021. Accessed December 27, 2021.
654 [https://www.epi-phare.fr/rapports-detudes-et-publications/myocardite-pericardite-](https://www.epi-phare.fr/rapports-detudes-et-publications/myocardite-pericardite-vaccination-covid19/)
655 [vaccination-covid19/](https://www.epi-phare.fr/rapports-detudes-et-publications/myocardite-pericardite-vaccination-covid19/)
- 656 35. Public health France. SARS-CoV-2 epidemics in 5-11 and 12-17-year children in
657 France. Évolution des indicateurs épidémiques chez les 5-11 ans et comparaison avec les 12-
658 17 ans. Published 2021. Accessed December 29, 2021.
659 [https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/enquetes-etudes/evolution-des-indicateurs-epidemiques-chez-les-5-11-ans-et-comparaison-avec-les-12-17-ans.-point-au-31-octobre-2021)
660 [respiratoires/infection-a-coronavirus/documents/enquetes-etudes/evolution-des-](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/enquetes-etudes/evolution-des-indicateurs-epidemiques-chez-les-5-11-ans-et-comparaison-avec-les-12-17-ans.-point-au-31-octobre-2021)
661 [indicateurs-epidemiques-chez-les-5-11-ans-et-comparaison-avec-les-12-17-ans.-point-au-31-](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/enquetes-etudes/evolution-des-indicateurs-epidemiques-chez-les-5-11-ans-et-comparaison-avec-les-12-17-ans.-point-au-31-octobre-2021)
662 [octobre-2021](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/enquetes-etudes/evolution-des-indicateurs-epidemiques-chez-les-5-11-ans-et-comparaison-avec-les-12-17-ans.-point-au-31-octobre-2021)
- 663 36. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine
664 against Covid-19 in Israel. *N Engl J Med*. 2021;385(23):2140-2149.
665 doi:10.1056/NEJMoa2109730
- 666 37. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large
667 Health Care Organization. *N Engl J Med*. 2021;385(23):2132-2139.
668 doi:10.1056/NEJMoa2110737
- 669 38. Belot A, Antona D, Renolleau S, et al. SARS-CoV-2-related paediatric inflammatory
670 multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020.
671 *Eurosurveillance*. 2020;25(22):2001010. doi:10.2807/1560-7917.ES.2020.25.22.2001010
- 672 39. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S.
673 Children and Adolescents. *N Engl J Med*. Published online June 29, 2020.
674 doi:10.1056/NEJMoa2021680
- 675 40. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in
676 Children in New York State. *N Engl J Med*. Published online June 29, 2020.
677 doi:10.1056/NEJMoa2021756
- 678 41. Petersen LR, Sami S, Vuong N, et al. Lack of Antibodies to Severe Acute Respiratory
679 Syndrome Coronavirus 2 (SARS-CoV-2) in a Large Cohort of Previously Infected Persons. *Clin*
680 *Infect Dis*. 2021;73(9):e3066-e3073. doi:10.1093/cid/ciaa1685
681
- 682

Table 1. Characteristics of children with hyper inflammatory syndrome following COVID-19 mRNA in France.

Case	1	2	3	4	5	6	7	8	9
Sex	Male	Male	Male	Male	Male	Male	Female	Male	Male
Comorbidity	No	No	No	No	Type 1 diabetes	Osteochondritis	Leukemia	No	No
Overweight	No	No	No	No	No	Yes	No	No	No
Number of COVID-19 mRNA injection	2	1	1	2	1	1	1	2	2
COVID-19 mRNA vaccine	BNT162b2	BNT162b2	BNT162b2	BNT162b2	BNT162b2	BNT162b2	BNT162b2	BNT162b2	BNT162b2
Delay from COVID-19 mRNA last injection to symptoms onset	26 days (50 days from first injection)	6 days	6 days	2 days (24 days from first injection)	4 days	20 days	19 days	42 days (72 days from first injection)	7 days (28 days from first injection)
MIS-C WHO criteria	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Details of MIS-C WHO criteria	Fever > 3 days, mucocutaneous involvement, Cardiac involvement, Elevated markers of inflammation, No other obvious microbial cause	Fever > 3 days, Shock, Cardiac involvement, Coagulopathy, Acute gastrointestinal symptoms, Elevated markers of inflammation, No other obvious microbial cause	Fever > 3 days, mucocutaneous involvement, Shock, Cardiac involvement, Coagulopathy, Acute gastrointestinal symptoms, Elevated markers of inflammation, No other obvious microbial cause	Fever > 3 days, Cardiac involvement, Coagulopathy, Acute gastrointestinal symptoms, Elevated markers of inflammation, No other obvious microbial cause	Fever > 3 days, mucocutaneous involvement, Shock, Cardiac involvement, Acute gastrointestinal symptoms, Elevated markers of inflammation, No other obvious microbial cause	Fever > 3 days, mucocutaneous involvement, Cardiac involvement, Elevated markers of inflammation, No other obvious microbial cause	Fever > 3 days, Coagulopathy, Acute gastrointestinal symptoms, Elevated markers of inflammation, No other obvious microbial cause	Fever > 3 days, Coagulopathy, Cardiac involvement, Acute gastrointestinal symptoms, Elevated markers of inflammation, No other obvious microbial cause	Fever > 3 days, mucocutaneous involvement, Cardiac involvement, Acute gastrointestinal symptoms, Elevated markers of inflammation, No other obvious microbial cause
Other manifestations	Lymphopenia, Cervical lymphadenopathy	Acute renal failure, proteinuria, Cytolytic hepatitis, Neurological involvement, Polyserositis, Hypereosinophilia.	Lymphopenia, Coronary dilation.	Acute renal failure, Cytolytic hepatitis, Pyelitis, Ileocolitis.	Cervical lymphadenopathy, Hypereosinophilia, Acute generalized exanthematous pustulosis.	Lymphopenia.	Macrophage activation syndrome, Cytolytic hepatitis.	Lymphopenia, Cervical lymphadenopathy, Cytolytic hepatitis.	Lymphopenia, Ileitis.
<i>Biological features</i>									
CRP, mg/L	250	300	257	228	70	97	49	167	186
Ferritinemia	527	195	600	Not performed	309	9185	25 020	430	Not performed

(µg/L)										
Hemoglobin (g/dL)	12.6	11.6	10.6	14.6	NA	NA	15.6	12.3	11.5	
Leucocytes (/mm ³)	16 500	11 130	16 600	4 050	NA	12 800	1 250	10 000	8 690	
Neutrophils (/mm ³)	15 500	4 340	13 000	Not performed	NA	9 700	1 040	9 400	7 600	
Lymphocytes (/mm ³)	520	3 560	900	Not performed	NA	890	100	920	540	
Eosinophils (/mm ³)	20	2 000	310	Not performed	1 170	NA	0	220	10	
Platelets (/mm ³)	225 000	472 000	278 000	321 000	204 000	350 000	27 000	230 000	113 000	
<i>SARS-CoV-2 infection documentation</i>										
Past history of SARS-CoV-2 infection	No	No	No	No	Yes (documented SARS-CoV-2 infection 7 months before)	No	No	No	No	No
Nasopharyngeal SARS-CoV-2 PCR	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
SARS-CoV-2 antibody	Anti-Spike: positive Anti-N: negative	Anti-Spike: positive Anti-N: negative	Anti-Spike: positive Anti-N: positive	Anti-Spike: positive Anti-N: positive	Anti-Spike: positive Anti-N: negative	Anti-Spike: positive Anti-N: negative	Anti-Spike: negative Anti-N: negative	Anti-Spike: positive Anti-N: limit of significance*	Anti-Spike: positive Anti-N: positive	Anti-Spike: positive Anti-N: positive
Specific therapy	IVIg+ steroids	None	IVIg+ steroids	IVIg+ steroids	IVIg+ steroids followed by steroid pulse	IVIg+ steroids	IVIg+ steroids	Steroids	IVIg+ steroids	Steroid pulse
PICU transfer	Yes	Yes	No	No	Yes	No	No	No	No	No
LVEF ≤ 55%	Yes (55%)	NON	No	Yes (40%)	Yes	No	No	No	No	Yes (40%)
Hemodynamic support	No	Yes	No	No	Yes	No	No	No	No	No
Outcome	Favorable	Favorable	Favorable	Favorable	Favorable	Favorable	Favorable	Favorable	Favorable	Favorable
Causality of COVID-19 mRNA (WHO AEFI classification)	A1	A1	B2	B2	A1	A1	B1	B1	B1	B2

*: antibody titer: 1.2 (Norms of the laboratory: positive: ≥ 1.68, negative: <0.49, limit: 0.49 ≤ x < 1.68).

Abbreviations: PCR: polymerase chain reaction. Anti-N: anti nucleocapsid. NA: missing data.

Table 2: Rate of hyper-inflammatory syndrome following COVID-19 mRNA vaccine compared to MIS-C post SARS-CoV-2 infection in 12-17-year-old children in France.

A) Reporting rate of hyper-inflammatory syndrome following COVID-19 mRNA vaccine in 12-17-year-old children

	Number of injected doses	Number of hyper-inflammatory syndrome	Reporting rate per 1,000,000 doses
Overall vaccination	8,113,058	9	1.1 [0.5; 2.1]
Excluding cases for which evidence of previous SARS-CoV-2 infection has been found	8,113,058	6	0.7 [0.3; 1.6]
First COVID-19 mRNA injection	4,079,234	5	1.2 [0.4; 2.9]
Second COVID-19 mRNA injection	3,905,636	4	1.0 [0.3; 2.6]
<i>Vaccination by sex</i>			
Males	4,126,275	8	1.9 [0.8; 3.8]
Females	3,986,783	1	0.3 [0.0; 1.4]

B) Rate of MIS-C following SARS-CoV-2 infection in 12-17-year-old children

	Estimated number of infected children	Number of MIS-C	Rate per 1,000,000 of infections
	1,147,150	130	113.3 [94.7; 134.6]
<i>MIS-C by sex</i>			
Males	587,086	74	126.0 [99.0; 158.2]
Females	560,064	56	100.0 [75.5; 129.8]

Abbreviations: MIS-C: multisystem inflammatory syndrome in children.

Table 3: Comparison of clinic-biological features of hyper-inflammatory syndrome following COVID-19 mRNA vaccine and MIS-C post SARS-CoV-2 infection in France.

	Hyper-inflammatory syndrome following COVID-19 mRNA vaccine (N=9)	MIS-C post SARS-CoV-2 infection (N=199)	P value
Clinical characteristics			
Sex ratio (F/M)	0.13	0.84	0.081
Age	12.5 [12.0; 13.5]	8.7 [4.8; 12.1]	
<i>Organ involvement following MIS-C WHO definition</i>			
Mucocutaneous involvement	5 (56%)	159 (80%)	0.097
Shock	3 (33%)	100 (50%)	0.318
Cardiac involvement	8 (89%)	125 (63%)	0.161
Including LVEF ≤ 55%	3 (33%)	52 (26%)	0.701
Coagulopathy	5 (56%)	82 (41%)	0.496
Digestive symptoms	7 (78%)	178 (89%)	0.261
<i>Other organ involvement</i>			
Cytolytic hepatitis	4 (44%)	36 (18%)	0.071
Lymphadenopathy	3 (33%)	39 (20%)	0.390
Renal failure	2 (22%)	31 (16%)	0.637
Neurological involvement	1 (13%)	65 (33%)	0.278
Biological features			
Maximal CRP, mg/L	186.0 [97.0; 250.0]	271.0 [187.2; 353.5]	0.031
Ferritinemia, (µg/L)	527.0 [369.5; 4892.5]	390.0 [206.0; 748.5]	0.228
Hemoglobin, g/dL	12.3 [11.6; 13.6]	11.0 [10.1; 11.0]	0.022
Leucocytes, /mm ³	10 560 [7 530; 13 720]	9 945 [7 000; 14.155]	0.768
Neutrophils, /mm ³	9 400 [5 970; 11 350]	8 090 [5 245; 12 065]	0.940
Lymphocytes, /mm ³	890 [530; 910]	1 000 [690; 1 805]	0.217
Eosinophils, /mm ³	220 [15; 740]	100 [5; 220]	0.463
Platelets, /mm ³	230 000 [204 000; 321 000]	186 000 [142 000; 277 500]	0.336
Short term outcomes			
PICU transfer	3 (33%)	143 (72%)	0.022
Hemodynamic support	2 (22%)	86 (43%)	0.307
Hospital length of stay	7.0 [7.0; 9.0]	8.0 [6.0; 12.0]	0.960

Categorical variables are described with numbers (percentages) and quantitative variables are described with median (IQR). Abbreviations: MIS-C: multisystem inflammatory syndrome in children.